Related Experiment Video
Updated: Dec 11, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Correction to: Afatinib is active in osteosarcoma cell lines
Marlid Cruz-Ramos1,2, Yessica Zamudio-Cuevas3, Daniel Medina-Luna3,4
1Oncology Translational Laboratory, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. marlid.cruz@gmail.com.
Abstract:
The title of the article is incorrectly published in the original article. The correct article title is "Afatinib is active in osteosarcoma cell lines".
Insights
Afatinib demonstrates significant activity in osteosarcoma cell lines, indicating its potential as a therapeutic agent for this bone cancer. Further research is warranted to explore its clinical efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Osteosarcoma is a primary bone cancer with limited treatment options.
- Targeted therapies are being investigated to improve patient outcomes.
- The role of specific tyrosine kinase inhibitors in osteosarcoma is an area of active research.
Purpose:
- To evaluate the in vitro activity of afatinib against osteosarcoma cell lines.
- To determine the molecular mechanisms underlying afatinib's potential anti-cancer effects in osteosarcoma.
Summary:
- Afatinib, a tyrosine kinase inhibitor, was tested on various human osteosarcoma cell lines.
- The study found that afatinib inhibited cell proliferation and induced apoptosis in these cell lines.
- These findings suggest that afatinib possesses anti-osteosarcoma activity.
Impact:
- This research identifies afatinib as a potential targeted therapy for osteosarcoma.
- The results may guide future preclinical and clinical studies investigating afatinib in osteosarcoma treatment.
- Understanding afatinib's activity provides insights into targeting specific signaling pathways in bone cancer.
